Further analysis showed that the prevalence of EGFR L858R mutations was significantly different between early and advanced-stage NSCLC, but the frequencies of EGER 19Del and other EGFR mutations (excluding EGFR L858R substitution and 19Del) were not significantly different. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.